INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

Nanotechnology in Target Drug Delivery System : A Comprehensive Review

Yash Saini, Ashish Kushwaha*, Dr. Arun Kumar Maurya, Dr. Lalit Bisht

JBIT College of Pharmacy.

ARTICLE INFO

Published: 27 Nov 2026
Keywords:
Nanotechnology in Target Drug Delivery System
DOI:
10.5281/zenodo.24582485

ABSTRACT

Nanotechnology has emerged as an important area of pharmaceutical research because of its potential to improve the delivery of medicines within the body. Targeted drug delivery uses nanoscale carriers to transport therapeutic agents towards specific tissues, organs, or cells. Depending on their composition and design, these carriers can improve the solubility of poorly soluble drugs, protect medicines from premature degradation, and control the rate at which drugs are released. hey may also help reduce drug exposure to healthy tissues and minimise unwanted side effects, although the results depend on the formulation and type of treatment.Various nanocarriers, including liposomes, polymeric nanoparticles, solid lipid nanoparticles, micelles, and dendrimers, are being investigated for their role in modern medicine. Their potential applications include cancer treatment, gene delivery, infectious diseases, neurological disorders, and inflammatory conditions. Despite these developments, several challenges remain, particularly in relation to toxicity, immune responses, long-term stability, large-scale manufacturing, production costs, and regulatory approval. This review examines the major types of nanocarriers, the mechanisms involved in targeted drug delivery, their pharmaceutical applications, and their key advantages and limitations. It also discusses future prospects and the need for further research to establish the safety and effectiveness of these systems in clinical practice

INTRODUCTION

Nanotechnology is an emerging field of science that focuses on the study and application of materials at the nanoscale, generally ranging from 1 to 100 nanometres.

At this scale, materials may exhibit physical, chemical, and biological properties that differ from those observed in their larger forms. These unique characteristics have created new opportunities in pharmaceutical research, particularly in the development of advanced drug delivery systems.

Targeted drug delivery is an approach designed to transport medicines towards a specific organ, tissue,

***Corresponding Author:** Ashish Kushwaha
Address: JBIT College of Pharmacy
Email : yashsaini57677787@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

cell, or site within the body. Its main objective is to improve the delivery of a drug to the area requiring treatment while limiting unnecessary exposure to other parts of the body.

This may help improve therapeutic outcomes and reduce certain unwanted side effects.

Conventional drug delivery methods often distribute medicines throughout the body, even when treatment is required only at a particular site.

As a result, some medicines may affect healthy tissues, while only a limited amount reaches the affected area. These problems can be especially challenging when drugs have poor solubility, limited stability, or significant side effects.

Nanotechnology offers potential solutions through the development of nanoscale carriers that can encapsulate or attach drugs, protect them during transport, and release them under suitable conditions. Examples include liposomes, polymeric nanoparticles, solid lipid nanoparticles, micelles, and dendrimers. Their size, surface characteristics, composition, and attached targeting molecules can be modified to influence how they interact with biological tissues and cells.

Although nanotechnology-based drug delivery has shown promising results, its effectiveness depends on the formulation, the drug being delivered, and the condition being treated. Further research is needed to understand its limitations and establish the safety and reliability of different systems. Therefore, studying these technologies is important for understanding their current role and future potential in pharmaceutical science.



Figure 1: ***Conceptual overview of nanotechnology-based targeted drug delivery.***

2.1 Research Question

How can nanotechnology-based drug delivery systems improve the delivery of medicines to specific sites in the body while enhancing treatment effectiveness and reducing unwanted side effects?

2.2 Significance of the Study

The study of nanotechnology-based targeted drug delivery is important because conventional drug delivery methods may not always provide sufficient drug concentrations at the required site or prevent unwanted effects on healthy tissues. Nanocarriers offer alternative approaches to addressing some of these limitations.

The major areas of significance include:

- Improving the delivery of medicines to specific tissues or cells.
- Enhancing the solubility and bio-availability of poorly water-soluble drugs.
- Protecting sensitive drugs from premature degradation within the body.
- Supporting controlled or sustained drug release over a period of time.
- Potentially reducing drug exposure to healthy tissues in suitable applications.
- Facilitating the delivery of biological medicines, genetic material, and other complex therapeutic agents.
- Supporting the development of new treatment approaches for various diseases.

2.3 Objectives

The main objective of this review is to examine the role of nanotechnology in targeted drug delivery and understand its potential contribution to pharmaceutical development. The specific objectives are:

- To explain the basic principles and importance of targeted drug delivery.
- To describe the major types of nanocarriers used in pharmaceutical applications.
- To discuss the mechanisms involved in drug targeting, transport, and release.

- To review the applications of nanotechnology in cancer treatment, gene delivery, infectious diseases, and other medical conditions.
- To evaluate the potential advantages and limitations of nanotechnology-based delivery systems.
- To examine future prospects and the challenges that must be addressed before these technologies can be used more widely.

3. LITERATURE REVIEW

3.1 Overview of Previous Research

Over the years, researchers have investigated nanotechnology as a way to improve drug delivery, particularly in terms of drug stability, distribution, solubility, and controlled release. Different types of nanocarriers have been developed to overcome some of the limitations associated with conventional drug delivery methods. Among these, liposomes and polymeric nanoparticles have received considerable attention because of their ability to carry different therapeutic agents and their potential for surface modification.

The development of liposomal medicines demonstrates that nanotechnology-based formulations can progress from laboratory research to clinical use. Doxil, a liposomal formulation of doxorubicin, is one example used in the treatment of certain cancers. By encapsulating an established anticancer drug within a liposomal carrier, the formulation changes how the drug is distributed in the body and can influence its safety profile.

Recent research has also focused on advanced nanocarriers designed to respond to specific conditions within the body. These include systems that release drugs in response to changes in pH, temperature, or other biological signals. Researchers are further exploring surface-modified nanoparticles that can interact with selected cellular targets, hybrid carrier systems that combine different materials, and nanocarriers for delivering genetic material such as DNA and RNA. Despite these developments, further investigation is required to establish the effectiveness, safety, and practical suitability of many newer approaches.

3.2 Types of Nanocarriers Used in Targeted Drug Delivery

Nanocarriers are nanoscale systems designed to transport drugs and other therapeutic substances within the body. They differ in their composition, structure, drug-loading capacity, and release mechanisms. The selection of a suitable carrier depends on the properties of the drug, the intended treatment site, and the desired therapeutic effect.

3.2.1 Liposomes

Liposomes are small, generally spherical vesicles made of one or more phospholipid bilayers. Their structure includes a watery interior, which can accommodate water-soluble drugs, while lipid-soluble drugs can be incorporated into the lipid layers. This arrangement makes liposomes useful for carrying different types of therapeutic agents.

Advantages:

- Can carry both water-soluble and lipid-soluble drugs.
- May protect certain drugs from premature degradation.
- Can be prepared using materials with suitable biocompatibility.
- Their surfaces can be modified to influence drug distribution and targeting.

Applications: Liposomes are used in selected anticancer and antifungal formulations and are also being investigated for delivering biological therapeutic agents.

3.2.2 Polymeric Nanoparticles

Polymeric nanoparticles are small drug carriers made from natural or synthetic polymers. Depending on the formulation, the drug may be enclosed within the polymer matrix, trapped in its structure, or attached to the particle surface. Some polymers are biodegradable, allowing the carrier to break down under suitable biological conditions.

Advantages:

- Can provide controlled or sustained drug release.

- May protect sensitive therapeutic agents during transport.
- Particle size and surface properties can be adjusted.
- Biodegradable materials can be used in suitable formulations.

Applications: These nanoparticles are being studied for cancer treatment, vaccine delivery, and the controlled release of various therapeutic agents.

3.2.3 Solid Lipid Nanoparticles

Solid lipid nanoparticles are carriers in which the drug is incorporated into a lipid core that remains solid under suitable storage and physiological conditions. Surfactants are generally used to stabilise the particles and help maintain their dispersion. These systems have attracted interest as alternatives to certain conventional lipid-based drug carriers.

Advantages:

- Can incorporate selected drugs into lipid-based matrices.
- May protect some drugs from chemical degradation.
- Offer the potential for sustained drug release.
- May improve the delivery of certain poorly water-soluble drugs.

Applications: Solid lipid nanoparticles are being investigated for oral, topical, and selected injectable drug delivery formulations.

3.2.4 Polymeric Micelles

Polymeric micelles are nanoscale structures formed by certain amphiphilic polymers in a suitable liquid environment. They generally contain an inner region that can accommodate water-insoluble drugs and an outer layer that interacts with the surrounding aqueous medium. This structure makes them particularly relevant to research on drugs with poor water solubility.

Advantages:

- Can improve the apparent solubility of some hydrophobic drugs.
- Their small size may support drug transport through certain biological environments.
- Some formulations may prolong drug circulation.
- Drug release can be adjusted through changes in polymer composition and structure.

Applications: Polymeric micelles are being investigated for delivering poorly water-soluble anticancer drugs and other hydrophobic therapeutic agents.

3.2.5 Dendrimers

Dendrimers are highly branched, tree-like molecules with a well-defined molecular structure. Their internal spaces and numerous surface functional groups provide opportunities to carry drugs or attach therapeutic and targeting molecules. Their properties can be modified by changing the chemical groups present on their surfaces.

Advantages:

- Have a relatively well-defined and organised molecular structure.
- Provide multiple sites for attaching therapeutic agents.
- Allow surface modification for specific functions.
- May combine drug delivery with targeting or diagnostic capabilities.

Applications: Dendrimers are being investigated for the delivery of anticancer agents, genetic material, and diagnostic compounds. Their wider use depends on addressing concerns such as toxicity, formulation complexity, and biological compatibility.

3.2.6 Metallic and Magnetic Nanoparticles

Metallic and magnetic nanoparticles have attracted interest because of their potential uses in diagnosis, imaging, and treatment. Gold nanoparticles and certain other metallic materials are being studied for imaging and light-based therapies. Magnetic nanoparticles may respond to an external magnetic field under appropriate conditions, offering possible applications in imaging and experimental drug-targeting approaches.

Advantages:

- Potential use in imaging and therapeutic applications.
- Surface modification can support the attachment of drugs or targeting molecules.
- Some systems may combine diagnostic and therapeutic functions.
- Magnetic or optical properties may offer additional functions beyond drug transport.

Applications: These nanoparticles are being investigated for diagnostic imaging, experimental targeted drug delivery, and selected cancer-treatment approaches.

However, their use requires careful assessment of toxicity, tissue accumulation, clearance from the body, and long-term safety. Overall, the performance of a nanocarrier depends on its composition, particle size, surface characteristics, drug-loading capacity, release behaviour, and interactions with biological systems. No single carrier is suitable for every drug or disease, so the choice of formulation must be based on the intended application and its safety requirements.



Figure 2: ***Common nanocarrier types used in pharmaceutical drug delivery.***

DISCUSSION

4.1 Mechanisms of Targeted Drug Delivery

Targeted drug delivery uses different approaches to help medicines reach specific tissues or cells. The effectiveness of each approach depends on the nanocarrier, the drug, and the biological environment.

4.1.1 Passive Targeting

Passive targeting relies on natural differences between healthy and diseased tissues. For example, some tumours have more permeable blood vessels and reduced lymphatic drainage, which may allow certain nanoparticles to accumulate in tumour tissue. This phenomenon is known as the enhanced permeability and retention (EPR) effect. However, its effectiveness varies between tumour types and patients, so consistent targeting cannot always be achieved. [3,6]

4.1.2 Active Targeting

Active targeting involves attaching molecules such as antibodies, peptides, or other ligands to the surface of a nanocarrier. These molecules are designed to recognise specific receptors or features on target cells, potentially improving binding and cellular uptake. However, the success of this approach depends on receptor availability and the properties of the carrier.

4.1.3 Stimuli-Responsive Targeting

Stimuli-responsive nanocarriers are designed to release their drug contents in response to particular internal or external triggers. Common examples include:

- **Changes in pH:** Differences in acidity can trigger drug release.
- **Temperature variations:** Changes in temperature may alter the carrier's structure and release behaviour.

- **Enzymatic activity:** Specific enzymes can trigger the breakdown of a carrier or release of its contents.
- **Light or magnetic stimulation:** External stimuli may help control drug release in selected formulations.

These systems may improve control over the timing or location of drug release. However, their effectiveness depends on whether the trigger operates safely and reliably under the intended conditions.



Figure 3: ***Comparison of passive and active targeting strategies.***

4.2 Mechanism of Action

Nanotechnology-based drug delivery systems work through a series of steps that help transport a medicine to its intended site and release it in a controlled manner. The exact mechanism depends on the type of nanocarrier, the drug being used, the route of administration, and the target tissue. The main steps involved are described below.

- **Drug Loading:** The process begins with incorporating the drug into the nanocarrier or attaching it to its surface. Depending on the carrier's structure and chemical properties, the medicine may be enclosed within its core, trapped in its matrix, or bound to its outer surface. This can help protect the drug from premature degradation and influence its release.
- **Administration:** After preparation, the formulation is administered through a suitable route, such as oral, topical, or injectable delivery. The route is selected according to the nature of the drug, the condition being treated, and the intended site of action.
- **Transport and Targeting:** Following administration, the nanocarrier travels through the body or moves towards the affected area. Its size, surface properties, and composition can influence its distribution, circulation time, and interaction with biological tissues. Certain formulations are designed to accumulate preferentially at specific sites, although the extent of targeting may vary.
- **Cellular Interaction and Uptake:** When the nanocarrier reaches the target tissue, it may interact with the surface of the target cells. Depending on its design, the carrier or its drug content may enter the cells through processes such as endocytosis. In other formulations, the medicine may be released outside the cells and then enter them separately.
- **Drug Release and Therapeutic Action:** The final step involves releasing the drug from the nanocarrier so that it can produce its intended therapeutic effect.

Drug release may occur gradually or in response to particular conditions, such as changes in pH, temperature, or enzymatic activity. The rate and location of release depend on the formulation and its interaction with the biological environment.

Overall, nanotechnology-based drug delivery systems aim to improve the transport, stability, and release of medicines. However, their performance varies according to the formulation and the patient's biological conditions.



Figure 4: ***Main steps involved in nanocarrier-based drug delivery.***

4.3 Pharmaceutical Applications

Nanotechnology-based drug delivery systems are being investigated for a wide range of medical conditions because they can influence how medicines are transported, distributed, and released within the body. Their potential applications include cancer treatment, neurological disorders, gene therapy, infectious diseases, and chronic inflammatory conditions. Although several nanotechnology-based medicines are already used in clinical practice, many newer approaches are still under research and require further evaluation.

4.3.1 Cancer Treatment

Cancer treatment is one of the major areas of research in nanotechnology-based drug delivery. Conventional anticancer medicines may affect both cancerous and healthy cells, which can lead to unwanted side effects. Nanocarriers can alter the distribution of these medicines and may help improve drug delivery to tumour tissues.

For example, liposomal doxorubicin (Doxil) is an established nanotechnology-based formulation used for certain cancers. Encapsulating doxorubicin in liposomes changes its distribution within the body and can influence its safety profile. However, the therapeutic benefits and potential risks depend on the specific formulation, type of cancer, and individual patient.

4.3.2 Brain Drug Delivery

Delivering medicines to the brain is challenging because the blood–brain barrier (BBB) restricts the entry of many substances from the bloodstream into the central nervous system. Although this barrier protects the brain from harmful agents, it also limits the effectiveness of several therapeutic drugs.

Researchers are therefore investigating nanoparticles and surface-modified carriers that may improve the delivery of selected medicines across this barrier. Potential applications include the treatment of brain tumours and neurological disorders such as Alzheimer's and Parkinson's diseases. Despite these possibilities, achieving safe, reliable, and effective drug delivery to the human brain remains a significant challenge.

4.3.3 Gene and Nucleic Acid Delivery

Nanotechnology also has an important role in the delivery of genetic material, including DNA and RNA. These molecules can be difficult to deliver because they may degrade rapidly in the body and have limited ability to enter cells on their own. Nanocarriers, particularly lipid-based nanoparticles, can help protect nucleic acids from degradation and facilitate their uptake by target cells. Such delivery systems are used in some vaccines and are also being investigated for gene therapy and other genetic treatments.

Their effectiveness depends on factors such as the stability of the carrier, successful cellular uptake, and the ability to deliver the genetic material to the appropriate location within the cell.

4.3.4 Infectious Diseases

Nanotechnology-based drug delivery systems are being studied for the treatment of bacterial and fungal infections. Nanocarriers may protect antimicrobial medicines from premature degradation, modify their distribution in the body, and provide controlled or

sustained drug release. These properties may be useful when developing formulations intended to improve drug delivery to infected tissues. Researchers are also exploring whether certain nanomaterials can contribute directly to antimicrobial activity.

However, the use of nanocarriers does not automatically overcome antimicrobial resistance, and their effectiveness and safety must be established for each formulation and intended application.



Figure 5: ***Potential pharmaceutical applications of nanotechnology-based delivery.***

4.3.5 Inflammatory and Chronic Diseases

Nanocarriers are also being investigated for the management of chronic and inflammatory conditions, including rheumatoid arthritis, inflammatory bowel disease, and diabetes. In these conditions, prolonged treatment may be required, making controlled drug release and improved delivery important areas of research. Certain formulations are designed to increase drug availability at affected tissues or maintain therapeutic levels over a longer period. These approaches may help improve treatment effectiveness and reduce unwanted effects in selected cases. Nevertheless, their clinical value depends on the specific disease, the drug being delivered, and the ability of the formulation to achieve reliable results.

4.4 Advantages of Nanotechnology in Targeted Drug Delivery

Nanotechnology-based drug delivery systems offer several potential advantages over conventional drug formulations. These benefits depend on the type of nanocarrier, the properties of the drug, and the intended therapeutic application.

- **Improved Drug Solubility:** Some nanocarriers can improve the apparent solubility and dispersion of drugs that dissolve poorly in water. This may help improve drug formulation and, in certain cases, increase the amount of medicine available for absorption.
- **Protection of Drugs:** Encapsulation within a nanocarrier can protect a drug from premature degradation caused by enzymes, chemical reactions, or other environmental factors. This may help maintain drug stability until it reaches the intended site or is released from the carrier.
- **Controlled Drug Release:** Nanocarriers can be designed to release medicines gradually over a specific period or in response to particular conditions, such as changes in pH or enzymatic activity. Controlled release may help maintain therapeutic drug levels and reduce the need for frequent administration in selected cases.
- **Modified Drug Distribution:** The size, composition, and surface characteristics of nanocarriers can influence how medicines circulate and distribute throughout the body. Certain formulations may increase drug accumulation in particular tissues, although the extent of this effect varies between formulations and patients.
- **Potential Reduction in Toxicity:** By modifying drug distribution and limiting exposure to certain healthy tissues, nanocarriers may reduce specific adverse effects. However, this benefit is not

guaranteed, as the carrier itself may also cause unwanted biological effects.

- **Versatility:** Different types of nanocarriers can be used to deliver a variety of therapeutic agents, including small-molecule drugs, proteins, peptides, and nucleic acids. This versatility makes nanotechnology useful for exploring new approaches to treatment.
- **Multifunctionality:** Some nanocarrier systems can combine drug delivery with imaging or diagnostic functions. Such systems may support the monitoring of treatment or the study of drug distribution within the body. However, their practical usefulness depends on the design and clinical application.

4.5 Limitations and Challenges

Despite their potential benefits, nanotechnology-based drug delivery systems face several scientific, technical, economic, and regulatory challenges. Addressing these limitations is essential for ensuring that nanomedicines are safe, effective, and suitable for widespread clinical use.



Figure 6: ***Examples of stimuli that can trigger drug release from responsive nanocarriers.***

- **Toxicity and Safety Concerns:** Certain nanomaterials may cause cellular damage, inflammation, immune reactions, or unwanted accumulation in organs and tissues. Their safety depends on factors such as particle size, composition, surface properties, dose, and duration of exposure. Therefore, careful evaluation of both short-term and long-term effects is necessary.
- **Manufacturing Difficulties:** Producing nanocarriers on a commercial scale while maintaining consistent quality can be challenging. Variations in particle size, shape, drug-loading capacity, purity, and release behaviour may affect the performance of the final product. Reliable manufacturing methods and strict quality-control procedures are therefore essential.
- **Stability Problems:** Some nanocarrier formulations may experience aggregation, changes in particle structure, or leakage of the encapsulated drug during storage. These problems can affect product quality, shelf life, and therapeutic performance. Suitable formulation methods and storage conditions are required to maintain stability.
- **High Production Costs:** The development of nanomedicines may require specialized equipment, advanced characterization techniques, and extensive testing. These requirements can increase research, manufacturing, and quality-control costs, potentially limiting the affordability and availability of some products.
- **Biological Barriers:** Nanocarriers must interact with complex biological environments and overcome barriers such as mucus, cell membranes, immune-system clearance, and, in some applications, the blood–brain barrier. These barriers can reduce the amount of drug reaching the intended tissue and make effective delivery more difficult.
- **Variable Targeting Efficiency:** Targeting performance may differ according to the type of disease, the characteristics of the affected tissue, and individual patient physiology. Consequently, a formulation that performs well under laboratory

conditions may not produce the same results in every patient. More reliable targeting strategies and further clinical studies are needed.

- **Regulatory Requirements:** Nanotechnology-based medicines require careful assessment of their quality, safety, and therapeutic effectiveness. Their complex composition and behaviour may require detailed characterization and product-specific evaluation. The US Food and Drug Administration (FDA) has published guidance addressing drug products containing nanomaterials and the application of nanotechnology to regulated products.

Overall, overcoming these challenges will require continued research, improved manufacturing techniques, appropriate safety testing, and cooperation between pharmaceutical scientists, clinicians, manufacturers, and regulatory authorities.

4.6 Future Prospects

The future of nanotechnology-based targeted drug delivery will likely depend on the development of safer, more effective, and more reliable formulations. Ongoing research is exploring biodegradable nanocarriers that can break down safely within the body, as well as targeting molecules designed to recognize particular receptors or biological features on target cells. These approaches may help improve drug delivery while limiting unnecessary exposure to healthy tissues.

Another promising area involves stimuli-responsive nanocarriers, which are designed to release their drug contents in response to specific conditions, such as changes in pH, temperature, or enzymatic activity. Hybrid nanocarriers that combine the properties of different materials may also provide new ways to improve drug stability, targeting, and controlled release. However, the effectiveness of these systems must be demonstrated through appropriate experimental and clinical studies.

Artificial intelligence (AI) and computer modelling may further support nanomedicine research by helping scientists analyse formulation characteristics, predict drug-release behaviour, and identify promising carrier designs. These tools could make the development process more efficient, although their predictions must be validated experimentally.

Personalized nanomedicine is another potential direction for future research. In this approach, drug delivery systems may eventually be adapted to individual patient characteristics, disease patterns, or treatment requirements. Such developments could support more tailored treatment strategies, but their practical implementation will require reliable diagnostic information and evidence of clinical benefit.

Despite these opportunities, several important steps remain before many emerging technologies can be used widely. Strong clinical evidence, long-term safety assessment, affordable production methods, consistent large-scale manufacturing, and clear regulatory pathways will be essential. With continued research and careful evaluation, nanotechnology may contribute to improved drug delivery and the development of more effective treatment options in the future.

CONCLUSION

Nanotechnology has emerged as a promising approach for improving the delivery of medicines within the body. Various nanocarriers, including liposomes, polymeric nanoparticles, solid lipid nanoparticles, micelles, and dendrimers, can influence drug solubility, stability, distribution, and release.

These systems are being explored for several pharmaceutical applications, such as cancer treatment, gene delivery, neurological disorders, infectious diseases, and inflammatory conditions. Their ability to modify drug delivery and release patterns offers opportunities to improve therapeutic outcomes in selected cases.

Despite these developments, several challenges remain before nanotechnology-based drug delivery can be adopted more widely. Although some nanomedicines are already used in clinical practice, many newer targeting approaches are still under investigation.

Potential toxicity, formulation stability, manufacturing difficulties, high production costs, and regulatory requirements must be carefully addressed to ensure the safety, quality, and effectiveness of these systems.

In conclusion, nanotechnology-based targeted drug delivery represents an important and evolving area of pharmaceutical research. Continued scientific investigation, improvements in formulation design, and

thorough clinical evaluation will be necessary to establish its long-term benefits and limitations.

With further progress, these systems may contribute to safer and more effective treatments and support the development of medicines better suited to individual patient needs.

6. ACKNOWLEDGEMENT

I would like to express my sincere and heartfelt gratitude to my esteemed faculty members and the Department of Pharmacy for their valuable guidance, constant encouragement, and unwavering support throughout the preparation of this review article. Their insightful suggestions, constructive feedback, and academic assistance have played a significant role in deepening my understanding of the subject and in helping me organize, analyze, and present the information included in this work in a clear and meaningful manner. I am also sincerely thankful to all the researchers, authors, and scientists whose published studies, research findings, and scientific contributions have provided valuable insights into the role of nanotechnology in targeted drug delivery. The scientific databases, peer-reviewed research publications, textbooks, and regulatory resources consulted during the preparation of this review served as important and reliable sources of information, enabling me to develop a broader, more comprehensive, and well-informed understanding of the topic. Furthermore, I acknowledge that this review article has been prepared solely for academic purposes as a part of my Bachelor of Pharmacy (B.Pharm) coursework, and it reflects my sincere effort to study and summarize the relevant scientific literature on nanotechnology-based targeted drug delivery systems. Finally, I am deeply grateful to everyone whose guidance, encouragement, scholarly contributions, and support have directly or indirectly contributed to the successful completion of this article.**REFERENCES**

REFERENCES

1. U.S. Food and Drug Administration. Drug Products, Including Biological Products, that Contain Nanomaterials: Guidance for Industry. 2022. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-products-including-biological-products-contain-nanomaterials-guidance-industry
2. U.S. Food and Drug Administration. Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology: Guidance for Industry. 2014. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considering-whether-fda-regulated-product-involves-application-nanotechnology
3. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nature Reviews Cancer. 2017;17:20–37. https://doi.org/10.1038/nrc.2016.108
4. Barenholz Y. Doxil®—The first FDA-approved nano-drug: lessons learned. Journal of Controlled Release. 2012;160 (2):117–134. https://doi.org/10.1016/j.jconrel.2012.03.020
5. Recent advances in nanomaterials-based targeted drug delivery for preclinical cancer diagnosis and therapeutics. Pharmaceutics. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10376516/
6. Targeted liposomal drug delivery: Overview of the current applications and challenges. Pharmaceutics. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11204409/
7. Nanoparticle-based materials in anticancer drug delivery: Current and future prospects. Frontiers in Pharmacology. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10637937/
8. Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews. 2013;65 (1):36–48. https://doi.org/10.1016/j.addr.2012.09.037
9. U.S. Food and Drug Administration. Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation. 2018. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/liposome-drug-

products-chemistry-manufacturing-and-controls-human-pharmacokinetics-and

10. Liu Y, Castro Bravo KM, Liu J. Targeted liposomal drug delivery: a nanoscience and biophysical perspective. Nanoscale Horizons. 2021;6:78–94. https://doi.org/10.1039/D0NH00605J
11. Cheng X, Xie Q, Sun YS. Advances in nanomaterial-based targeted drug delivery systems. Frontiers in Bioengineering and Biotechnology. 2023;11:1177151. https://doi.org/10.3389/fbioe.2023.1177151
12. Venkatraman SS, Ma LL, Natarajan JV, Chattopadhyay S. Polymer- and liposome-based nanoparticles in targeted drug delivery. Frontiers in Bioscience (Scholar Edition). 2010;2 (3):801–814. https://doi.org/10.2741/s103
13. Khodaverdi H, Zeini MS, Moghaddam MM, Vazifedust S, Akbariqomi M, Tebyaniyan H. Lipid-based nanoparticles for the targeted delivery of anticancer drugs: A review. Current Drug Delivery. 2022;19 (10):1012–1033. https://doi.org/10.2174/1567201819666220117102658
14. Senjab RM, AlSawaftah N, Abuwatfa WH, Husseini GA. Advances in liposomal nanotechnology: from concept to clinics. RSC Pharmaceutics. 2024;1:928–948. https://doi.org/10.1039/D4PM00176A
15. Beach MA, Nayanathara U, Gao Y, Zhang C, Xiong Y, Wang Y, Such GK. Polymeric nanoparticles for drug delivery. Chemical Reviews. 2024;124 (9):5505–5616. https://doi.org/10.1021/acs.chemrev.3c00705
16. Hristova-Panusheva K, Xenochodidis C, Georgieva M, Krasteva N. Nanoparticle-mediated drug delivery systems for precision targeting in oncology. Pharmaceuticals. 2024;17 (6):677. https://doi.org/10.3390/ph17060677
17. Prakash S. Nano-based drug delivery system for therapeutics: a comprehensive review. Biomedical Physics & Engineering Express. 2023;9 (5). https://doi.org/10.1088/2057-1976/acedb2
18. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology. 2007;2:751–760. https://doi.org/10.1038/nnano.2007.387
19. Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nature Reviews Drug Discovery. 2014;13:813–827. https://doi.org/10.1038/nrd4333
20. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nature Reviews Drug Discovery. 2021;20:101–124. https://doi.org/10.1038/s41573-020-0090-8

HOW TO CITE: Yash Saini, Ashish Kushwaha, Dr. Arun Kumar Maurya, Dr. Lalit Bisht, Nanotechnology in Target Drug Delivery System : A Comprehensive Review, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 11, 5658-5669. https://doi.org/10.5281/zenodo.24582485